

 EFDA FEDERAL ETHIOPIAN DRUGS AUTHORITY ETHIOPIAN FOOD & DRUG AUTHORITY	PHARMACOVIGILANCE & CLINICAL TRIAL LEAD EXECUTIVE OFFICE		FORM_SOP_PVCT_CT_PROC_008_02	
	FORMAT FOR CLINICAL TRIAL INFORMATION SHARED TO THE PUBLIC		REVISION NO.004	PAGE 1 OF 1

UNIQUE ID NO.	STUDY TITLE	RESEARCH INTEREST AREA	INTERVENTIONS	STUDY SITE	STATUS (S)	DATE OF APPROVAL
ET-CT-0005	Sanitation, Water and Instruction in face washing for Trachoma (SWIFT)	Trachoma	Procedure	Waghamera zone	Ongoing	13/03/2019
ET-CT-0006	Kebele Elimination of Trachoma for Ocular health (KETEFO) trial	Trachoma	Mixed	North Shewa (Amhara region)	Ongoing	10/07/2020
ET-CT-0011	Safety and Efficacy of Dolutegravir and EFV400 for Pregnant and breast-feeding Women: a randomized non inferiority clinical trial /PREGART/	HIV	Conventional medicine	AA, South region, Oromia region	Ongoing	15/01/2021
ET-CT-0026	A phase I clinical investigation to the safety of two herbal ointment formulations for an intended treatment of Tinea corporis/cruris (ClinHerb1)	Traditional medicine	Traditional medicine	ALERT	Ongoing	26/05/2025
ET-CT-0033	Assessing new pediatrics tablets of primaquine as radical cure in Ethiopia	Malaria	Conventional medicine	Arbaminch	Ongoing	05/06/2024
ET-CT-0036	Feasibility, safety, and efficacy of concomitant curcumin in patients undergoing palliative radiotherapy for FIGO stage IIIB-IVA cervical cancer: An open-label pilot trial	Cancer	Traditional medicine	Black lion Hospital	Ongoing	24/07/2024
ET-CT-0037	Methotrexate and Prednisolone study in Erythema Nodosum Leprosum International (MaPs in ENL): A Randomized clinical trial in acute, Chronic and recurrent ENL	Leprosy	conventional medicine	ALERT	Ongoing	07/11/2023
ET-CT-0038	Operational feasibility of appropriate radical cure of plasmodium vivax with tafenoquine or primaquine after semi-quantitative G6PD testing in Ethiopia: a mixed methods study	Malaria	conventional medicine	ALERT	Ongoing	01/02/2024
ET-CT-0039	A randomized, open-label, phase-II, single-centre study to evaluate the efficacy, safety, and pharmacokinetics of LXE408 in patients with primary visceral leishmaniases in Ethiopia.	Leishmaniasis	conventional medicine	Gonder	Ongoing	29/11/2023

THIS DOCUMENT IS THE PROPERTY OF THE EFDA. DISCLOSURE OF THE CONTENTS TO ANY THIRD PARTY WITHOUT WRITTEN CONSENT OF EFDA IS FORBIDDEN

Amir

Mog

 EFDA ETHIOPIAN FOOD & DRUG AUTHORITY	PHARMACOVIGILANCE & CLINICAL TRIAL LEAD EXECUTIVE OFFICE		FORM_SOP_PVCT_CT_PROC_008_02	
	FORMAT FOR CLINICAL TRIAL INFORMATION SHARED TO THE PUBLIC		REVISION NO.004	PAGE 1 OF 1

ET-CT-0041	Single Dose Oral BE study of Primaquine 15mg tablet (test product) and Primaquine 15 mg (reference product) in healthy adult human subjects under fasting conditions	Bioequivalence	conventional medicine	AHRI	Ongoing	05/06/2024
ET-CT-0042	A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria -Tafenoquine Dosing revised	Malaria	conventional medicine	Arbaminch	Ongoing	14/08/2024
ET-CT-0043	Reducing mortality in adults with advanced HIV disease, a randomized, double blinded, placebo-controlled, multicenter trial of azithromycin prophylaxis for advanced HIV disease	HIV	conventional medicine	Asela, Jimma, Mekele, Adama	Ongoing	16/12/2024
ET-CT-0045	Peer-led HIV care and the UNAIDS 90-90-90 treatment targets in Sidama Ethiopia: A cluster randomized trial and economic evaluation of Teach-Test- Link-Trace model (TTLT) trial	HIV testing	Procedure	Sidama Region	Ongoing	07/02/2025
ET-CT-0046	Serological testing and treatment for p.vivax malaria: cluster randomized in Ethiopia	Malaria	conventional medicine	West Arsi, Oromia	Ongoing	18/08/2025

Prepared by: Abebe Telile

Signature: Amir

Date: 02/09/2025

Approved by: _____

Signature: _____

Date: 02/09/2025

Assef Alemu
 Head Executive Officer
 Pharmacovigilance and
 Clinical Trial

THIS DOCUMENT IS THE PROPERTY OF THE EFDA. DISCLOSURE OF THE CONTENTS TO ANY THIRD PARTY WITHOUT WRITTEN CONSENT OF EFDA IS FORBIDDEN